Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 30Carcinoma, Renal Cell 17Prostatic Neoplasms 13Carcinoma, Transitional Cell 11Melanoma 8Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Uterine Cervical Neoplasms 6Kidney Neoplasms 6Non-Muscle Invasive Bladder Neoplasms 5Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Neoplasm Metastasis 4Colorectal Neoplasms 4Carcinoma, Merkel Cell 4Squamous Cell Carcinoma of Head and Neck 3Head and Neck Neoplasms 3Carcinoma, Hepatocellular 3Urothelial Cancer 2Testicular Neoplasms 2Stomach Neoplasms 2Neoplasms 2Lung Neoplasms 2Hodgkin Disease 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinoma in Situ 2Carcinoma 2

Interventions

durvalumab 1Vinblastine 1Methotrexate 1Gemcitabine 1Doxorubicin 1Cystectomy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bladder Adenocarcinoma × durvalumab × Genitourinary × Clear all
NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Stanford University

Phase 2 Terminated
7 enrolled 9 charts
GenitourinarySarcoma

Bladder Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡